Related Experiment Video
Updated: Aug 11, 2026

Use of Artificial Sputum Medium to Test Antibiotic Efficacy Against Pseudomonas aeruginosa in Conditions More Relevant to the Cystic Fibrosis Lung
Published on: June 5, 2012
Treatment of Pseudomonas aeruginosa infections with pyocines
Abstract:
The interactions of a contractile, a filamentous and a small pyocine with a sensitive strain of Pseudomonas aeruginosa (no. P14) were examined in vivo. The purification procedure used yielded high-activity pyocine preparations that were not toxic to mice. The inhibitory activity of such preparations, when injected into mice by various routes, was retained for up to 24 h. However, high molecular-weight pyocines given intraperitoneally in the presence of a lethal dose of strain P14 administered by the same route did not prevent the fatal outcome of infection unless they are given before or together with the bacteria. The small pyocine had no protective effect. In burned mice infected with strain P14, topical application of a filamentous pyocine failed to improve the chances of survival. The results suggest that there is little future for pyocine therapy.
Insights
Pyocine therapy, using contractile and filamentous pyocines against Pseudomonas aeruginosa, showed limited effectiveness in vivo. These pyocines did not prevent fatal infections when administered with bacteria, suggesting limited therapeutic potential.
Area of Science:
- Microbiology
- Pharmacology
- Infectious Diseases
Background:
- Pseudomonas aeruginosa is an opportunistic pathogen.
- Pyocines are bacteriocins with potential antimicrobial activity.
- In vivo efficacy of pyocines requires investigation.
Purpose of the Study:
- To evaluate the in vivo efficacy of contractile, filamentous, and small pyocines against Pseudomonas aeruginosa (strain P14).
- To assess the therapeutic potential of pyocines in a mouse model of infection.
Main Methods:
- Purification of high-activity, non-toxic pyocine preparations.
- Administration of pyocines via various routes (intraperitoneal, topical) in mice.
- Infection challenge with a lethal dose of Pseudomonas aeruginosa strain P14.
Main Results:
- Pyocine inhibitory activity was retained in vivo for up to 24 hours.
- High molecular-weight pyocines did not prevent fatal infections when given with bacteria.
- Topical application of filamentous pyocine did not improve survival in burned mice.
- Small pyocine offered no protective effect.
Conclusions:
- Pyocine therapy demonstrated limited efficacy in preventing or treating Pseudomonas aeruginosa infections in vivo.
- Timing of administration is critical for high molecular-weight pyocines, but overall therapeutic potential appears restricted.
- Further research into pyocine therapy is unlikely to yield significant clinical benefits.
Related Concept Videos
Hand hygiene
Hand washing...
Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy
Acute Pyelonephritis II: Diagnostic Studies and Management
Gene Regulation in Microbial Communities: Quorum Sensing
Atypical Pneumonia
Inhibitors of Bacterial DNA Synthesis

